What does this research mean for the field?

Epigallocatechin-3-gallate (EGCG) demonstrates potent preclinical anticancer activity in colorectal cancer by inhibiting cell proliferation, inducing apoptosis via multiple signaling pathways, and reducing tumor growth in vivo. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This review aims to summarize the preclinical evidence of epigallocatechin-3-gallate (EGCG) as an anticancer agent in colorectal cancer (CRC).

July 26, 2026CancersOpen Access

Epigallocatechin-3-Gallate (EGCG) as a Multifaceted Natural Anticancer Agent in Colorectal Cancer: Preclinical Evidence and Future Directions

View Full Paper

Ask AI

Bookmark

Authors

NANicolaos AchilleosBrock University MHMaddox Talbot HarrisonBrock University ETEvangelia TsianiBrock University

Discussion

Member takes

Implication

Review summarizes preclinical evidence of EGCG's anticancer effects in colorectal cancer, suggesting its potential as a novel therapy.

Key Points

This review aims to summarize the preclinical evidence of epigallocatechin-3-gallate (EGCG) as an anticancer agent in colorectal cancer (CRC).
In vitro studies on EGCG's effects on colorectal cancer cells, assessing cell proliferation, migration, and apoptosis.
In vivo studies using mouse xenograft models to evaluate tumor growth and mass reduction operations.
EGCG inhibits cell proliferation and migration in vitro.
EGCG induces apoptosis through modulation of Wnt/β-catenin, PI3K/Akt, and NF-κB pathways.
In vivo, EGCG significantly reduces tumor growth and volume.

Cite This Study

Achilleos et al. (2026) studied this question.

synapsesocial.com/papers/6a65a84ed3aea3239cd78c9d https://doi.org/10.3390/cancers18152391

View Full Paper

Ask AI

Bookmark